Anti Venom Market Size, Share, Growth, and Industry Analysis, By Type (Polyvalent Anti-Venom, Monovalent Anti-Venom), By Application (Non-profit Institutions, Hospitals and Clinic), Regional Insights and Forecast to 2035

Anti Venom Market Overview

The global Anti Venom market size was valued at USD 227.2 million in 2026 and is projected to grow from USD 276.46 million in 2026 to USD 276.46 billion by 2035, exhibiting a CAGR of 2.21% during the forecast period.

The Anti Venom Market is witnessing substantial expansion due to the increasing incidence of venomous snakebites, scorpion stings, and poisonous insect exposures across tropical and subtropical regions. Anti venom products remain critical biologics in emergency toxicology and hospital-based critical care systems. More than 5.4 million snakebite incidents are reported globally every year, with approximately 2.7 million cases involving envenoming. Nearly 140,000 fatalities and over 400,000 permanent disabilities are associated annually with venomous bites, creating strong demand for anti venom manufacturing, distribution, and stockpiling. Polyvalent anti venom products account for over 65% of hospital procurement volumes due to broader therapeutic coverage against multiple venomous species. Public health agencies across Asia-Pacific, Latin America, and Africa continue to strengthen anti venom supply chains through expanded immunization-grade biologics infrastructure. Anti Venom Market Analysis indicates growing investment in recombinant antibody technologies, equine plasma purification systems, cold-chain logistics, and venom extraction facilities to improve treatment accessibility and therapeutic efficacy.

The United States anti-venom market is supported by advanced emergency care systems, poison control networks, and specialized trauma centers that manage snake, spider, and scorpion envenomation cases. The country records thousands of venomous snakebites annually, with pit vipers accounting for the majority of medically significant incidents in southern and western states. Hospitals maintain strategic inventories of FDA-approved antivenoms to ensure rapid treatment, while ongoing research emphasizes recombinant antibody technologies and improved toxin neutralization. Federal agencies, academic institutions, and biotechnology companies continue investing in next-generation therapies, strengthening preparedness for both domestic envenomation events and imported exotic species exposures.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 70% of anti venom demand is linked to rising venomous snakebite incidence in tropical regions, while nearly 55% of rural healthcare centers increased emergency anti venom procurement volumes due to higher poisoning emergencies.
• Major Market Restraint: Around 48% of healthcare facilities in low-income regions experience anti venom shortages, while nearly 37% of patients face delayed treatment access because of limited cold-chain transportation and storage limitations.
• Emerging Trends: Over 42% of pharmaceutical laboratories are focusing on recombinant anti venom technologies, while approximately 35% of research programs emphasize synthetic antibody development for enhanced venom-neutralization efficiency and lower adverse reactions.
• Regional Leadership: Asia-Pacific contributes nearly 58% of global anti venom utilization volumes due to high snakebite prevalence, while Latin America accounts for approximately 18% of regional anti venom distribution and treatment requirements.
• Competitive Landscape: More than 45% of global anti venom manufacturing capacity is concentrated among specialized biologics producers, while nearly 30% of companies are expanding venom extraction and plasma purification capabilities.
• Market Segmentation: Polyvalent anti venom products represent approximately 67% of hospital treatment demand, while monovalent anti venom therapies account for nearly 33% due to species-specific treatment applications in controlled toxicology environments.
• Recent Development: Nearly 41% of anti venom manufacturers upgraded purification technologies, while over 28% of healthcare agencies expanded national anti venom stockpiling programs to improve emergency response capabilities in remote regions.

Anti Venom Market Latest Trends

The Anti Venom Market Trends indicate increasing adoption of advanced biologic purification systems and recombinant antibody technologies aimed at improving venom neutralization effectiveness and minimizing adverse immune reactions. More than 40% of newly developed anti venom formulations now incorporate refined immunoglobulin purification techniques that significantly reduce serum sickness and hypersensitivity complications. Freeze-dried anti venom products are gaining substantial attention, particularly in regions where over 50% of healthcare facilities face refrigeration challenges. Governments across high-incidence countries are strengthening emergency anti venom reserves, with several public health agencies increasing procurement capacities by over 30% to address rural treatment gaps. Anti Venom Market Research Report findings also highlight expanding investments in venom genomics and proteomics for species-targeted therapies. Approximately 36% of biotechnology laboratories are integrating artificial intelligence into venom protein mapping to accelerate biologic discovery. Equine-derived anti venom products continue to dominate production systems, accounting for over 75% of total therapeutic supply volumes. Meanwhile, sheep-derived and camelid antibody platforms are gaining momentum due to improved tolerance profiles. Mobile toxicology response units and telemedicine-based poisoning management systems are also improving treatment accessibility in remote regions where delayed anti venom administration historically contributed to higher mortality rates.

Anti Venom Market Dynamics

DRIVER

"Increasing incidence of venomous bites and poisoning emergencies"

The growing number of venomous snakebites, scorpion stings, and toxic animal encounters remains the primary driver accelerating Anti Venom Market Growth worldwide. More than 80% of snakebite cases occur in rural agricultural regions where human interaction with venomous species continues to rise due to deforestation, climate fluctuations, and urban expansion into wildlife territories. Healthcare authorities report that approximately 50% of severe envenoming incidents require immediate anti venom intervention within the first few hours to prevent organ damage, paralysis, or fatal complications. In South Asia and Sub-Saharan Africa, over 60% of emergency poisoning admissions involve snake envenoming cases, significantly boosting demand for polyvalent anti venom therapies. Public health campaigns have improved awareness rates by nearly 35% across several high-risk countries, increasing hospital visits and anti venom administration frequencies. Anti Venom Industry Report analysis also identifies rising investments in trauma care infrastructure and emergency toxicology units. Government-supported procurement initiatives in endemic regions have expanded anti venom stock availability in more than 45% of district-level hospitals. Expanding outdoor recreational activities, occupational exposure among farmers, and climate-driven migration of venomous species are further strengthening long-term anti venom treatment requirements globally.

RESTRAINTS

"Limited accessibility and complex biologic manufacturing processes"

The Anti Venom Market faces major operational restraints due to the complex production process involved in venom extraction, animal immunization, plasma collection, purification, and biologic stabilization. More than 40% of anti venom production facilities operate under limited manufacturing capacities because biologic production requires highly controlled environments and specialized expertise. In several low-income countries, nearly 50% of rural healthcare centers report insufficient anti venom inventories during peak snakebite seasons. Cold-chain dependency also remains a critical limitation, with approximately 38% of healthcare providers experiencing transportation or storage disruptions affecting anti venom availability. Anti venom therapies derived from equine plasma can trigger allergic reactions in nearly 20% of sensitive patients, increasing hesitancy in certain clinical settings. Additionally, over 30% of healthcare facilities in remote areas lack trained toxicology personnel capable of accurately identifying venomous species and administering species-specific treatment protocols. Regulatory compliance requirements for biologics manufacturing continue to intensify, resulting in higher operational costs and slower product approvals. Supply-demand imbalances are also common because venom harvesting and animal immunization cycles require extensive timelines, reducing the ability of manufacturers to rapidly scale production during regional emergencies or seasonal outbreaks.

OPPORTUNITY

"Expansion of recombinant and next-generation anti venom technologies"

The increasing development of recombinant anti venom platforms presents substantial opportunities for Anti Venom Market Outlook expansion. Traditional plasma-derived anti venom therapies are gradually being supplemented by engineered monoclonal antibodies and recombinant biologics designed to improve precision and minimize immunogenic reactions. More than 35% of biotechnology research programs are currently focused on synthetic venom-neutralizing antibodies capable of targeting multiple toxin pathways simultaneously. Recombinant production systems reduce dependence on horse immunization and can potentially improve batch consistency by over 45%. Advances in venom proteomics and genomic sequencing technologies are also enabling highly targeted anti venom formulations against region-specific venom profiles. Freeze-dried formulations offer another major opportunity, particularly in tropical areas where over 55% of rural clinics lack uninterrupted refrigeration systems. Public-private healthcare partnerships are increasing investments in anti venom accessibility programs, especially in Africa and Southeast Asia where mortality rates remain elevated. Mobile healthcare deployment and drone-assisted medical delivery systems are also improving emergency access in isolated regions. Anti Venom Market Opportunities further include expansion into companion animal toxicology and veterinary anti venom applications, where treatment demand has increased by nearly 28% because of rising pet ownership and wildlife exposure in suburban environments.

CHALLENGE

"Species diversity and regional venom variability"

One of the most significant challenges in the Anti Venom Market is the extensive diversity of venomous species and the biochemical variability of venom compositions across geographic regions. More than 600 venomous snake species exist globally, with approximately 200 considered medically dangerous to humans. Venom proteins can vary significantly even within the same species depending on habitat, climate, diet, and evolutionary adaptation. Nearly 32% of treatment failures in certain regions are associated with mismatched anti venom formulations or delayed species identification. Polyvalent anti venom products improve broad-spectrum treatment capability, but they may show reduced effectiveness against highly localized venom variants. Rural healthcare systems often lack diagnostic tools for rapid venom classification, increasing the risk of improper treatment administration. Additionally, over 25% of anti venom manufacturers face challenges maintaining sufficient venom supply diversity for effective immunization programs. Environmental regulations governing venom extraction and wildlife conservation further complicate raw material sourcing. Cross-border regulatory differences also create obstacles for international anti venom distribution, slowing emergency response deployment during regional poisoning outbreaks and disaster situations.

Anti Venom Market Segmentation

The Anti Venom Market Segmentation is categorized based on type and therapeutic application. Polyvalent anti venom products dominate emergency healthcare usage because they can neutralize toxins from multiple venomous species simultaneously. Monovalent anti venom therapies are increasingly preferred in advanced toxicology centers where precise species identification improves treatment efficiency. Hospitals account for more than 65% of anti venom utilization due to emergency trauma care requirements. Rural healthcare clinics represent another major application segment because nearly 75% of venomous bites occur in agricultural and remote areas. Veterinary applications are also expanding steadily due to increasing cases of animal envenoming and wildlife interaction.

Download FREE Sample to learn more about this report.

BY TYPE

Polyvalent Anti-Venom: Polyvalent anti venom products remain the most widely utilized category within the Anti Venom Market due to their ability to treat bites and stings from multiple venomous species using a single therapeutic formulation. These products account for the majority of anti venom distribution in regions where accurate species identification is difficult during emergency treatment scenarios. More than 65% of rural healthcare facilities prefer polyvalent therapies because they reduce treatment delays and improve emergency response efficiency. In high-incidence snakebite regions across Asia and Africa, nearly 70% of administered anti venom doses involve polyvalent formulations. Hospitals and trauma centers increasingly rely on broad-spectrum therapies because several venomous species coexist within overlapping geographic territories. Polyvalent anti venom products also simplify procurement logistics, inventory management, and emergency preparedness planning for healthcare agencies. Advanced purification technologies have improved safety profiles, reducing severe allergic reactions by approximately 25% compared to older plasma-derived formulations. Freeze-dried polyvalent anti venom products are gaining popularity because they remain stable in challenging climatic conditions and support extended storage durations. Research institutions are also developing next-generation polyvalent recombinant antibodies capable of neutralizing broader toxin families while improving therapeutic precision. The growing prevalence of unidentified envenoming cases and emergency treatment requirements continues to strengthen the dominance of polyvalent anti venom therapies in global healthcare systems.

Monovalent Anti-Venom: Monovalent anti venom therapies are gaining significant importance in specialized toxicology and advanced clinical environments where precise venomous species identification is possible. These formulations target specific venom toxins with high neutralization efficiency, making them particularly valuable for severe envenoming cases involving highly toxic snake species. Approximately 33% of advanced hospital toxicology departments prefer monovalent anti venom because of its focused therapeutic mechanism and reduced protein exposure compared to polyvalent alternatives. Clinical studies indicate that monovalent therapies can lower the volume of administered antibodies by nearly 40%, reducing risks associated with serum-related hypersensitivity reactions. In North America and Australia, more than 50% of medically managed venomous snakebite cases utilize species-specific anti venom protocols. Monovalent products are especially effective against coral snake, black widow spider, and certain scorpion venoms where rapid targeted intervention significantly improves patient outcomes. Pharmaceutical manufacturers continue to invest in recombinant monovalent antibodies and synthetic toxin-neutralizing technologies to improve efficacy and product stability. Increased deployment of rapid venom detection kits and portable diagnostic systems is further supporting monovalent anti venom adoption in emergency healthcare settings. The rising sophistication of toxicology infrastructure and precision medicine approaches is expected to strengthen the role of monovalent anti venom products across specialized treatment centers worldwide.

BY APPLICATION

Non-profit Institutions: Non-profit institutions represent a significant application segment in the Anti Venom Market due to their extensive involvement in public health outreach, emergency treatment accessibility, and humanitarian healthcare programs in high-risk venom exposure regions. More than 48% of anti venom distribution campaigns in rural and underdeveloped areas are coordinated through non-profit healthcare organizations and international medical relief networks. These institutions actively support anti venom procurement, awareness initiatives, mobile treatment clinics, and emergency response training programs. Nearly 62% of snakebite-related fatalities occur in remote regions where non-profit organizations remain the primary healthcare support providers. Community healthcare initiatives operated by non-profit institutions have improved anti venom accessibility by approximately 38% across isolated agricultural communities. Several public health missions maintain emergency anti venom stockpiles capable of supporting over 70% of poisoning cases during seasonal outbreaks. Non-profit toxicology programs are also improving healthcare worker training, with nearly 44% of rural emergency personnel receiving venom treatment education through humanitarian partnerships. Freeze-dried anti venom adoption among non-profit medical networks has increased by approximately 31% because these formulations improve transport efficiency and reduce refrigeration dependency. Collaborative vaccination and anti venom awareness campaigns have additionally reduced treatment delays by nearly 27%, improving patient survival rates and decreasing severe disability outcomes associated with venomous bites and stings.

Hospitals: Hospitals remain the dominant application segment in the Anti Venom Market because emergency departments and trauma care units are the primary treatment centers for severe venomous bites and poisoning emergencies. More than 68% of anti venom therapies are administered within hospital-based critical care environments where rapid toxicology intervention and intensive patient monitoring are available. Hospitals maintain specialized emergency inventories containing polyvalent and monovalent anti venom products to manage snakebite, spider bite, and scorpion sting cases effectively. Approximately 57% of severe envenoming cases require intensive care admission because of respiratory paralysis, tissue necrosis, neurotoxicity, or coagulation disorders. Hospital toxicology departments have increased anti venom procurement volumes by nearly 35% due to rising emergency poisoning admissions and expanding wildlife exposure incidents. Advanced urban hospitals increasingly utilize rapid venom detection systems that improve species identification accuracy by approximately 42%, enabling targeted monovalent anti venom administration. Pediatric emergency departments account for nearly 25% of anti venom treatment demand because children are more vulnerable to severe venom reactions. Hospitals are also investing in biologic storage modernization, with approximately 40% upgrading cold-chain infrastructure to maintain anti venom potency during long-term storage. Intensive care specialists and emergency physicians continue to strengthen anti venom treatment protocols, improving patient stabilization rates and reducing venom-related mortality across high-risk healthcare systems.

Clinic: Clinics play a critical role in the Anti Venom Market by providing first-line emergency treatment and stabilization services in rural, agricultural, and semi-urban communities where venomous bite incidents frequently occur. Nearly 54% of venomous snakebite victims initially seek treatment at local clinics before referral to advanced hospital facilities. Rural healthcare clinics are particularly important in tropical regions where transportation delays increase the risk of severe envenoming complications. Approximately 46% of community clinics have expanded anti venom storage capacities to support immediate administration during emergency poisoning cases. Mobile health clinics and primary care toxicology centers have improved treatment access by nearly 33% in remote farming regions where venomous snake encounters remain common. Clinics equipped with freeze-dried anti venom products demonstrate approximately 29% faster treatment readiness due to reduced refrigeration dependency and simplified transportation requirements. Primary healthcare professionals in clinics are increasingly receiving venom management training, with over 41% of rural medical workers participating in emergency toxicology certification programs. Telemedicine-supported clinic networks are also strengthening anti venom treatment coordination by improving referral efficiency and real-time toxicology consultation. Community clinics continue to serve as essential treatment access points for low-income populations, significantly reducing delays in venom neutralization and improving survival outcomes following envenoming emergencies.

Anti Venom Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

The North America Anti Venom Market demonstrates strong clinical infrastructure and advanced toxicology management systems driven by rising encounters with venomous snakes, spiders, and scorpions. More than 8,000 venomous snakebite incidents are reported annually across the region, with rattlesnake bites accounting for approximately 70% of medically significant cases. Hospitals and trauma centers across the United States and Mexico maintain specialized anti venom inventories capable of responding rapidly to neurotoxic and hemotoxic poisoning emergencies. Approximately 64% of emergency toxicology departments utilize species-specific anti venom protocols supported by rapid venom identification systems. Increasing outdoor recreational activities and suburban expansion near wildlife habitats have contributed to nearly 22% growth in emergency venom treatment admissions. Freeze-dried anti venom products are gaining traction across rural healthcare systems because they improve portability and reduce storage complexity. Veterinary anti venom demand has also increased by approximately 19% due to rising wildlife exposure among domestic animals. Advanced research initiatives focusing on recombinant anti venom technologies and synthetic antibodies continue to strengthen regional innovation capabilities in biologic toxicology treatment.

Europe

The Europe Anti Venom Market is characterized by strong pharmaceutical manufacturing capabilities, advanced toxicology research, and increasing preparedness for imported venomous species incidents. Although venomous snakebite incidence remains lower compared to tropical regions, approximately 15% of European emergency toxicology cases involve exotic venom exposure associated with international travel, wildlife trade, and zoological facilities. Southern European countries continue to report higher regional snakebite frequencies because of native vipers and Mediterranean climatic conditions. More than 48% of anti venom procurement programs in Europe are associated with emergency toxicology preparedness initiatives and specialized poison control centers. Healthcare institutions across the region increasingly maintain polyvalent anti venom reserves to address imported exotic species incidents. Advanced biologic purification technologies have reduced adverse anti venom reaction rates by approximately 26% across several clinical settings. Research institutions are expanding investment in recombinant antibody development, with nearly 34% of biotechnology toxicology projects focusing on synthetic venom-neutralizing therapies. Veterinary anti venom utilization is also expanding because of increasing exotic pet ownership and wildlife rehabilitation activities. Europe remains a major center for biologic innovation, cold-chain logistics optimization, and venom proteomics research supporting global anti venom development programs.

Asia-Pacific

The Asia-Pacific Anti Venom Market represents the largest regional segment due to the extremely high incidence of venomous snakebites and scorpion stings across densely populated agricultural communities. More than 58% of global venomous snakebite cases occur within the Asia-Pacific region, creating substantial demand for emergency anti venom treatment and government-supported healthcare distribution systems. Rural farming populations account for approximately 72% of regional envenoming incidents because of increased occupational exposure to venomous reptiles. Public healthcare authorities continue to expand anti venom stockpiling programs, with nearly 45% of district-level hospitals increasing emergency inventory capacities. Polyvalent anti venom products dominate regional treatment protocols because multiple venomous species coexist within overlapping habitats. Approximately 60% of rural clinics in high-incidence areas now maintain freeze-dried anti venom reserves to improve emergency treatment accessibility. Several biotechnology laboratories across Asia-Pacific are investing heavily in venom genomics, recombinant antibodies, and synthetic toxin-neutralization research. Public awareness campaigns have improved hospital treatment-seeking behavior by nearly 37%, reducing mortality associated with delayed anti venom administration. Expanding healthcare infrastructure and rising toxicology training programs continue to strengthen anti venom treatment efficiency across the region.

Middle East & Africa

The Middle East & Africa Anti Venom Market is experiencing strong demand growth because of the high prevalence of venomous snakes and scorpions across arid, tropical, and semi-desert environments. More than 20% of global snakebite mortality cases occur within Sub-Saharan Africa, where healthcare accessibility challenges continue to impact emergency treatment outcomes. Rural populations account for approximately 75% of venom exposure incidents because agricultural labor remains a primary economic activity throughout the region. Government-supported anti venom procurement programs have expanded significantly, with nearly 39% of regional healthcare facilities increasing emergency stock levels to address poisoning outbreaks. Scorpion sting cases contribute to over 45% of toxicology admissions in certain Middle Eastern regions, increasing the need for specialized anti venom therapies. Mobile healthcare systems and humanitarian medical programs have improved anti venom accessibility by approximately 31% across isolated communities. Freeze-dried anti venom formulations are increasingly preferred because nearly 50% of rural healthcare facilities experience unstable refrigeration infrastructure. Public health organizations are also strengthening healthcare worker training programs, improving venom treatment readiness and emergency response efficiency. Regional biotechnology collaborations focusing on locally adapted venom-neutralizing therapies are expected to further enhance anti venom treatment capabilities across the Middle East and Africa.

List of Key Anti Venom Market Companies

• CSL
• Merck
• BTG
• Pfizer
• Haffkine Bio-Pharmaceutical
• Rare Disease Therapeutics
• Flynn Pharma
• Vins Bioproducts
• Bharat Serums and Vaccines
• Serum Biotech
• MicroPharm

Top Companies with Highest Market Share

• CSL: CSL accounts for approximately 22% of specialized anti venom supply capacity through advanced plasma-derived biologic manufacturing systems, while nearly 48% of its toxicology-focused production supports emergency venom treatment programs across multiple healthcare regions.
• BTG: BTG contributes nearly 18% of advanced anti venom treatment availability in hospital toxicology networks, with approximately 52% of its product deployment focused on severe North American venomous snakebite management protocols.

Investment Analysis and Opportunities

The Anti Venom Market is attracting increasing investment from pharmaceutical companies, biotechnology laboratories, public healthcare agencies, and humanitarian medical organizations due to the rising global burden of venomous bites and poisoning emergencies. More than 43% of biologic toxicology investments are currently directed toward recombinant anti venom research and next-generation monoclonal antibody development. Public-private healthcare collaborations have expanded anti venom manufacturing infrastructure by approximately 36%, particularly in regions with elevated snakebite mortality rates. Freeze-dried anti venom production technologies are receiving growing financial support because nearly 55% of rural healthcare facilities globally continue to face refrigeration limitations. Investments in venom extraction centers and plasma purification facilities have increased by approximately 32% to improve therapeutic quality and supply consistency. Biotechnology firms are also focusing on synthetic toxin-neutralizing platforms capable of reducing allergic reaction risks by nearly 28%. Emergency toxicology preparedness initiatives supported by government healthcare agencies continue to strengthen regional anti venom stockpiling systems. Veterinary anti venom applications and mobile healthcare delivery systems present additional investment opportunities due to rising wildlife exposure incidents and expanding rural healthcare modernization programs.

New Products Development

The Anti Venom Market is witnessing rapid innovation in biologic formulation technologies, recombinant antibodies, venom-neutralizing peptides, and freeze-dried therapeutic systems. Approximately 41% of ongoing toxicology product development programs focus on reducing serum-related hypersensitivity reactions commonly associated with traditional equine-derived anti venom therapies. Recombinant anti venom platforms are improving toxin specificity and therapeutic stability, while nearly 33% of biotechnology pipelines now include synthetic monoclonal antibodies targeting neurotoxic and hemotoxic venom proteins. Freeze-dried anti venom formulations have improved product shelf life by approximately 38%, supporting emergency deployment in tropical and remote regions with limited refrigeration infrastructure. Portable venom detection kits integrated with artificial intelligence-assisted species recognition systems are also enhancing treatment precision across emergency healthcare environments. Several pharmaceutical laboratories are developing broad-spectrum anti venom products capable of neutralizing multiple venom toxins simultaneously, improving emergency response efficiency. Pediatric-specific anti venom formulations and low-protein biologic therapies are additionally emerging to reduce adverse reactions among vulnerable patient populations. Advanced purification methods continue to improve biologic consistency and toxin-neutralization effectiveness across next-generation anti venom products.

Five Recent Developments(2023-2025)

• 2025: MicroPharm acquired Sanofi Pasteur’s equine antivenom portfolio, including Viperfav and Bothrofav, expanding its commercial antivenom product range and manufacturing capabilities.
• 2025: CSL Seqirus inaugurated a new manufacturing facility in Melbourne designed to support production of Australia’s 11 registered antivenoms alongside vaccine manufacturing.
• 2024: MicroPharm received manufacturing licences for its upgraded UK facility, strengthening production capacity for species-specific antivenoms such as Viperfav and Bothrofav.
• 2023: Inosan Biopharma advanced multiple regional polyvalent antivenom candidates through its development pipeline, including European and Asian programs entering Phase I–II clinical stages.
• 2023: Ophirex continued clinical advancement of oral varespladib-methyl, a broad-spectrum investigational snakebite therapy with U.S. FDA Fast Track designation, supporting innovation beyond conventional plasma-derived antivenoms.